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This study aimed to obtain and characterize a microemulsion (ME) containing phenobarbital (PB). 
The PB was incorporated in the proportion of 5% and 10% in a microemulsion system containing 
Labrasol®, ethanol, isopropyl myristate and purified water. The physicochemical characterization was 
performed and the primary stability of the ME was evaluated. An analytical method was developed using 
spectrophotometry in UV λ = 242 nm. The kinetics of the in vitro release (Franz model) of the ME and 
the emulsion (EM) containing PB was evaluated. The incorporation of PB into ME at concentrations of 
5 and 10% did not change pH and resistance to centrifugation. There was an increase in particle size, a 
decrease of conductivity and a change in the refractive index in relation to placebo ME. The ME remained 
stable in preliminary stability tests. The analytical method proved to be specific, linear, precise, accurate 
and robust. Regarding the kinetics of the in vitro release, ME obtained an in vitro release profile greater 
than the EM containing PB. Thus, the obtained ME has a potential for future transdermal application, 
being able to compose a drug delivery system for the treatment of epilepsy.
Uniterms: Microemulsion/physicochemical characterization. Microemulsion/In vitro release. 
Phenobarbital/microemulsion system/evaluation. Nanotechnology.
O objetivo deste trabalho foi obter e caracterizar uma microemulsão (ME) contendo fenobarbital (FEN). 
O FEN foi incorporado na proporção de 5% e 10% em um sistema microemulsionado composto por 
labrasol®, etanol, miristato de isopropila e água purificada. Foi realizada a caracterização físico-química 
e avaliada a estabilidade preliminar da ME. Desenvolveu-se um método analítico por espectrofotometria 
em UV λ = 242 nm. Foi avaliada a cinética de liberação in vitro (em modelo de Franz) da ME e da 
emulsão (EM) contendo FEN. A incorporação do FEN em ME nas concentrações de 5 e 10% não alterou 
o pH e a resistência à centrifugação. Houve aumento do tamanho da partícula, redução da condutividade 
e alteração do índice de refração em relação à ME placebo. A ME manteve-se estável nos ensaios de 
estabilidade preliminar. O método analítico demonstrou ser específico, linear, preciso, exato e robusto. 
Na cinética de liberação in vitro, a ME obteve um perfil de liberação in vitro superior a EM contendo 
FEN. Desta forma, a ME obtida tem potencial para uma futura aplicação transdérmica, podendo compor 
um sistema de liberação de fármacos para tratamento da epilepsia.
Uniterms: Microemulsão/caracterização físico-química. Microemulsão/cinética de liberação in vitro. 
Fenobarbital/sistema microemulsionado/avaliação. Nanotecnologia.
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INTRODUCTION
Approximately 50 million people worldwide are 
living with epilepsy (Gomes et al., 2002). It affects 
between 7 and 14 of each 1,000 people (WHO, 2015). It 
is one of the most common serious neurological disorders 
worldwide, which can be successfully controlled with one 
single antiepileptic. Uncontrolled seizures may result in 
injuries, embarrassment, anxiety, unpredictability, and 
occasionally may induce death (Dalmora et al., 2010).
Phenobarbital (PB – Figure 1) is a barbiturate that 
acts as a non-selective Central Nervous System depressant. 
It is widely used as an antiepileptic drug for it is complete 
and very effective drug and has advantages such as low 
cost, broad spectrum of action and ease of use (Dalmora et 
al., 2010). It is a centenarian drug and is still the best cost-
benefit pharmacological treatment for epilepsy, especially 
in developing countries (Brodie, Kwan, 2012).
Studies have shown that the pharmacokinetics of 
PB in children and young adults is age-dependent, and 
may have an absolute bioavailability of 48.9% among 
the pediatric population (Yukawa, Higuchi, Aoyama, 
1992; Marsot et al., 2013). In addition, comparing oral 
administration with the intramuscular route, there is a 
difference of about 60% in terms of bioavailability in 
newborns (Yukawa et al., 2011). Newborns present a late 
and incomplete oral absorption of PB when compared with 
intramuscular administration (Jalling, 1975). Furthermore, 
the narrow therapeutic margin of this anticonvulsant 
is one of the aggravating factors for the treatment of 
epileptic seizures, since the usual doses may lead plasma 
concentrations to toxic levels.
Recently, a great attention has been paid to the 
development of drug delivery systems using lipid 
microemulsions (ME) as carrier agents of drugs with a 
low aqueous solubility, such as PB (Üstündağ Okur et 
al., 2011). The drug penetration rate into the skin can be 
increased by the use of permeation enhancers (Williams, 
Barry, 2004), and MEs are known for increasing the 
availability of certain drugs into the deeper layers of the 
skin.
MEs are systems in which the internal phase is 
a dimensionally restricted microenvironment, with 
particular properties. It may bond or associate molecules 
with different polarities (Oliveira et al., 2004). They are 
generally characterized as spherical aggregates, and have 
diameters smaller than 1,400 Å, typically 100 Å (Yacubian, 
2002). They can be defined as thermodynamically stable, 
isotropic and as transparent systems with two immiscible 
liquids (usually water and oil) stabilized by a film of 
surfactant compounds (with or without co-surfactants) 
located in the oil/water interface (Lawrence, 1994; 
Üstündağ Okur et al., 2011).
In the literature, several PB quantification methods 
are described, such as titration (ANVISA, 2010), 
spectrophotometry (Boeris, Luco, Olsina, 2000), high 
performance liquid chromatography (HPLC) (Dalmora et 
al., 2010; ANVISA, 2010), and immunoassays (Spiehler 
et al., 1976; Pastore, Ofuchi, Nishiyama, 2007). Several 
pharmaceutical formulations were described, such as 
oral solution (Yska et al., 2000) and tablets (Goicoechea, 
Olivieri, 1998). It is necessary, therefore, to develop an 
analytical method for determining PB in ME. 
Most  pub l i ca t i ons  on  PB  quan t i f i ca t i on 
use biological samples. They generally consist of 
simultaneous quantifications with structurally similar 
drugs (Boeris, Luco, Olsina, 2000) and/or metabolites 
(Romer, Donaruma, Zuman, 1977) in blood. The Brazilian 
Pharmacopoeia describes an analytical method using 
spectrophotometric to determine drugs in solutions, which 
preconizes the solubilization of the drug in a borate buffer 
with a pH = 9.6 (ANVISA, 2010).
Djabri, Guy and Delgado-Charro (2012) showed that 
determining PB by iontophoresis was capable of penetrating 
skin layers. PB administered by organogel and oil 
formulation was capable of permeating the skin of healthy 
cats (Gasper et al., 2015). In a recent study conducted by 
our research group, Figueiredo et al. (2015) demonstrated 
that PB in nanocarriers reduced seizures and the death rate 
in the rats submitted to seizures using a model induced 
by pilocarpine. Further, the transdermal application of 
the formulation was capable of reducing oxidative stress 
and neuronal damage to the hippocampus of animals. 
In the market, an oral formulation containing 
cyclosporine in microemulsion (Sandimmun Neoral®) 
is used in immunosuppressive therapy. In addition, 
drugs are being marketed in adhesives for transdermal 
administration such as estradiol (Dermestriol®), fentanyl 
(Durogesic®), scopolamine (Scopoderm®), among others. 
Formulations containing microemulsions for transdermal 
administration are patent-protected worldwide (Figueiredo 
et al., 2013).
FIGURE 1 - Chemical structure of antiepileptic drug PB.
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Knowing that MEs are known for increasing the 
availability of certain drugs into the deeper layers of the 
skin and that the PB is a candidate drug for transdermal 
permeation, this study aimed to use MEs containing PB for 
transdermal use as a strategy for the treatment of epilepsy. 
In addition, its preliminary stability and physicochemical 
characterization were analyzed, an analytical method 
for the determination of PB in ME was developed and 
the kinetics of the in vitro release of PB into ME was 
performed.
MATERIAL AND METHODS
Chemicals
PB raw material was used as standard (PharmaNostra, 
lot no. 10083132B, content 100.18%, Brazil). The 
Labrasol® (caprylocaproyl macrogol-8 glycerides) was 
purchased from Gattefosse (France). Ethanol (EtOH) 
99.8% was purchased from Dinâmica (Brazil) and 
Vetec (Brazil). NaOH was acquired from Vetec (Brazil). 
The isopropyl myristate was purchased from Synth 
(Brazil). Purified water was obtained through reverse 
osmosis system (Milipore, Germany). Non-ionic self-
emulsifying wax (PharmaNostra, Brazil), methylparaben, 
propylparaben and propylene glycol (Vetec, Brazil), were 
used. The dialysis membrane was acquired from Sigma-
Aldrich (Brazil).
Preparation of the ME and incorporation of the PB
The ME was prepared as a cold mixture, under 
mild agitation, of Labrasol®, ethanol, isopropyl myristate 
and purified water. To design the pseudo-ternary phase 
diagram, proportions of surfactants and oil phase were 
fixed, followed by a drop-by-drop addition of purified 
water until the mixture became clear (microemulsion 
region). The PB was incorporated cold at concentrations of 
50 mg/g (ME50) and 100 mg/g (ME100). In the preparation 
EM 50 mg/g (EM50) and 100 mg/g (EM100), non-ionic 
self-emulsifying wax, methylparaben, propylparaben, 
propylene glycol and purified water were used (Table I).
Physicochemical characterization
In all characterization tests performed, the 
mean±standard deviation of triplicate samples was 
used (also in the ME placebo, and with 5-10% of the 
incorporated drug).
Solubilization Capacity
In order to assess the maximum solubilization 
capacity of PB in ME, a solubility test was performed 
according to the adapted methodology of Üstündağ Okur 
et al. (2011). An excess of PB in a test tube containing 3 mL 
of ME (n=3) was added, then proceeding to the following 
conditions: stirring at 100 rpm for 72 hours at 37±2 °C. 
Subsequently, it was centrifuged for 30 min at 3,000 
rpm. The sample was filtered; then, the filtered aliquots 
were transferred to a volumetric flask, supplementing it 
with a EtOH:NaOH mixture (pH 13, 0.1M) (50:50, v/v) 
(Boeris, Luco, Olsina, 2000). Readings were taken at UV 
λ = 242 nm.
Resistance to centrifugation
Samples of each formulation were subjected to 
centrifugation for 30 min at 3,000 rpm (HT, Brazil). Then, 
the occurrence or not of phase separation or any evidence 
of instability was observed. 
pH, conductivity and refractive index
The pH of the ME was evaluated using a digital 
potentiometer (Bel Engineering, Italy) with a glass 
electrode and a temperature sensor previously calibrated 
with pH 4.0 and 7.0 buffer solutions. The glass electrode 
was inserted directly inside the formulation. The 
conductivity was determined in an electrical conductivity 
meter (Marte, Brazil). The refractive index was determined 
using a refractometer (Quimis, Brazil) calibrated with 
purified water. Readings were taken at 25±2 ºC.
Viscosity
The viscosity of the formulations was assessed 
in a digital rotary viscometer (Quimis, Brazil) through 
variations in the rotational speed between 6 and 60 rpm 
using nº 4 (ME) and nº 1 spindles (EM).
Particle size and polydispersity index (PDI)
The nanometric droplet size analysis was made 
using dynamic light scattering technique. It provides the 
hydrodynamic radius of colloidal particles (Malvern, 
England). The system temperature was kept at 25 °C and 
the droplet diameter (nm) and PDI (polydispersity index) 
(n = 3) were calculated.
Preliminary stability
The study of preliminary stability was conducted 
by analyzing the following parameters: organoleptic 
characteristics, pH, electrical conductivity and content. 
In the organoleptic analysis of the formulations, their 
appearance, color, homogeneity and instability processes 
as creaming and phase separation were observed 
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(ANVISA, 2005). The parameters were analyzed at the 
beginning of the study and immediately after thermal 
stress tests, freeze-thaw cycle and 30 days at room 
temperature (25±2 °C). The drug content at 60 and 90 days 
after sample preparation was also evaluated.
The samples to the thermal stress were subjected to 
the temperatures in the range of 40-80 °C, with elevation 
progression of 10 °C/30minutes in thermostated water-
bath (Nova ética, Brazil). The formulations were evaluated 
at the end of 80 °C, after returning to room temperature 
(25±2 °C) (Baby et al., 2008). For the freeze-thaw cycle, 
the samples were subjected at -5°C ± 2 °C in a refrigerator 
(Electrolux, Brazil) for 24 h and 50 °C ± 2 °C for 24 h in 
an oven (Icamo, Brazil), completing a cycle. At the end 
of 12 days (6 cycles) the formulations were analyzed after 
returning to room temperature (25 °C) (ANVISA, 2004). 
ME formulations with and without PB at 5 and 10% were 
evaluated, besides the comparative study with EM.
Validation of the analytical method to determine 
PB in ME
Sample preparation and analysis conditions
EtOH:NaOH (pH 13, 0.1 M) (50:50, v/v) was a 
solvent used to design ithe calibration curve PB. Aliquots 
of a 1 mg/mL solution were transferred to 10 mL volumetric 
flasks. In the preparation of the samples, an amount of ME 
containing 5 mg of PB was weighed in a 10 mL volumetric 
flask (Bioprecisa, Brazil). The sample was diluted with an 
EtOH:NaOH solution by stirring it manually for about 60 
seconds. Then, an aliquot of this solution was transferred 
to another 10 mL volumetric flask containing the same 
solvent. All readings were made using spectrophotometry 
in the UV region at 242 nm using EtOH:NaOH as a blank 
solution (spectrophotometers Bioscience, England, and 
Shimadzu, Japan). The following analytical parameters 
were evaluated: specificity and selectivity, linearity 
and interval of the method, precision and accuracy, and 
robustness (ANVISA, 2003).
Specificity and selectivity
The following solutions were prepared: PB standard 
solution, solution of PB in ME, solution of ME without PB 
(placebo), and EtOH:NaOH solvent. A scan in the range 
of 200-400 nm was carried out and the absorption spectra 
shown by the curves were compared.
Linearity and interval of the method
A series of 7 dilutions in triplicate was conducted 
in the concentration range 1-24 µg/mL. The correlation 
coefficient was obtained by linear regression by the least 
squares method. Limits of detection (LOD) and limit of 
quantification (LOQ) were calculated according to RE 
no. 899/2003.
Precision and accuracy
The repeatability was evaluated by the mean of six 
sample determinations at a concentration of 12 µg/mL. 
In the intermediate precision assay, the between-run 
precision of sample determinations (n = 6) of a same 
concentration was evaluated within an interval of 48 hours 
of repeatability and performed by different analysts. The 
inter-laboratory precision (reproducibility) was performed 
on the same day under the same conditions of analysis in a 
laboratory B. Accuracy was assessed by adding PB in ME 
and its recovery percentage in three distinct concentration 
levels (n=3): 9.6, 12 and 14.4 µg/mL (80, 100 and 120% 
contents). 
Robustness
The robustness was evaluated by the change in 
sample preparation conditions by the method of stirring 
during its preparation. Magnetic manual stirring and 
different manufacturers of the ethanol solvent were 
compared. In order to evaluate the stability of the analyte, 
ME samples were prepared for spectrophotometric 
determination according to the previous procedure and 
were subjected to the presence and absence of light. The 
reading was performed at 242 nm in intervals of 0 h to 3.5 h.
Kinetics of the in vitro release of PB in ME
The kinetics of the in vitro release of ME50 was 
evaluated and compared with EM50. The study was 
conducted using dialysis membranes in Franz type diffusion 
cells with a diffusional area of 1.15 cm2 and a volume 
of ±14 mL. The receiver compartment was filled with 
borate buffer at a pH 9.6 associated with 10% of EtOH 
(previously defined) in a system composed of individual 
cells (37 ± 0.5 oC, 100 rpm). An amount of EM50 or ME50 
(containing 20 mg of PB) was applied into the receptor 
compartment directly on the membrane. Samples of the 
receiving solution were collected at 2, 4, 6, 8, 12 and 24 h. 
Readings of the collected aliquots were performed at UV 
λ=242 nm. The total volume of the receptor phase was 
replaced at each sampling time for replacement of the 
medium maintaining sink conditions (Carvalho et al., 2012).
Statistical analysis
The results obtained in the validation of the analytical 
method and in the stability study were submitted to the 
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Student’s t test to evaluate possible statistical differences 
with a statistical significance of p<0.05. For data analysis, 
the software Microsoft Office Excel®, OriginLab® and 
Graphpad Prism® were used. The linearity of the method 
was subjected to analysis of variance (ANOVA). 
RESULTS AND DISCUSSION
Obtaining ME and physicochemical 
characterization
Figure 2 shows a pseudo-ternary phase diagram, 
which may show the ME region. The adopted criterion 
for considering ME was the observation of clear, single 
phase, isotropic and low viscous systems. 
The formulations used in all tests of this work are 
described with their respective components on Table I.
In the investigation of the maximum solubility of PB 
in ME, the value 137.8±13.7 mg/mL was obtained, being 
2.3 times higher than recently published results considering 
an oral PB loaded microemulsion (Monteagudo et al., 
2013). The solubility of the drug in water is approximately 
1.0 to 1.2 mg/mL. The ME was as effective in solubilizing 
PB as aqueous solutions, with a high amount of co-
solvents such as propylene glycol at 50% (Shayanfar, 
Acree Jr, Jouyban, 2009) and ethanol at 80% (Attwood, 
Florence, Rothschild, 2003). Thus, it was possible to easily 
incorporate PB using mild stirring at concentrations of 5% 
and 10%, obtaining the formulations ME50 and ME100 
that were evaluated in this work. 
For the physicochemical characterization of ME 
placebo (ME) and formulations containing PB (ME50 
and ME100) the results shown on Table II were obtained. 
It was observed that the tested formulations showed no 
phase separation. The approval in this test is a sign of 
the stability of evaluated preparations. The formation 
of precipitates or phase separation indicates the need 
of recasting them (ANVISA, 2004). Thus, by the spin-
resistance test, a preliminary analysis of the presence of a 
possible physical instability was performed when PB was 
incorporated into ME.
The obtained formulations showed a pH compatible 
with the skin and without significant changes upon adding 
the drug (Table II). It is recommended that products with a 
prolonged permanence on the skin have a pH between 4.0 
and 7.0 (Rebello, 2005). That is, the pH should be near the 
skin’s pH range, i.e., from 4.6 to 5.8 (Leonardi, Gaspar, 
Campos, 2002; Campos, Frasson, 2011). 
The measurement of conductivity is an attempt to 
classify the type of formulation based on the distribution of 
the phases, allowing the determination of the conductivity 
of polar or apolar domains (Urban, 2004). The used 
TABLE I - Description of the formulations used in the accelerated stability study
Components
Formulation (% w/w)
ME ME50 ME100 EM EM50 EM100
Labrasol® 66.64 66.64 66.64 - - -
Ethanol 16.56 16.56 16.56 - - -
Isopropyl myristate 9.3 9.3 9.3 - - -
Non-ionic self-emulsifying wax - - - 12 12 12
Methylparaben - - - 0.1 0.1 0.1
Propylparaben - - - 0.01 0.01 0.01
Propylene glycol - - - 2 2 2
Purified water qsp. 100 100 100 100 100 100
Phenobarbital - 5 10 - 5 10
FIGURE 2 - Pseudo-ternary phase diagram. ME: microemulsion; 
SF: phase separation; ELO: Opaque liquid emulsion; ELL: 
Liquid-Milky emulsion.
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surfactant, Labrasol®, tends to form ME type O/A because 
its HLB value is 12 (Lawrence, Ress, 2000; Ash, Ash, 
2004; Gatefossé, 2016), favoring the formation of micelles 
with an oily internal phase. 
A small decrease in conductivity of ME was 
observed when the drug was incorporated into the 
system. This may characterize structural changes in ME 
by the incorporation of a hydrophobic molecule, since 
its conductivity is very sensitive to changes in the phase 
arrangement of a microemulsion system (Mo, Zhong, 
Zhong, 2000; Mehta, Kaur, 2011). Halle (1990) shows 
that the increase in the size of droplets in a ME O/A may 
influence the fluctuations of their charges, and thus reduce 
conductivity. A relation between the increase of droplets’ 
size and the reduction of the system conductivity (Table II) 
was observed. 
The refractive index can be used to determine the 
purity of solutions or the proportions with which certain 
liquids are mixed. It is the ratio of the light propagation 
speed in air and its speed in the substance (Longo, 2006). 
The refractive index of the ME50 formulation achieved a 
significant reduction, being closer to the value of purified 
water (1,333) and more distant from the value of Labrasol® 
(1,450-1,470) (Ash, Ash, 2004). The formulation ME100 
obtained a small but significant increase in its value, which 
may indicate the first signs of instability when increasing 
the drug content in the formulation. 
The nanosize of ME droplets was affected with the 
incorporation of the drug. However, it remained within 
the ME range, i.e., 10-150 nm (Silva et al., 2009), or, 
according to Damasceno et al. (2011), 10-300 nm (Table 
II). The increase in droplet diameter might suggest the 
location of the drug in the interfacial layer of surfactants, 
which may decrease the curvature of the micelle and thus 
change the size of the droplets (Gomes, 2010). The PDI 
value lower than 0.5 indicates homogeneity of the droplet 
size (Üstündağ Okur et al., 2011), which did not occur with 
the ME placebo. The incorporation of the drug may have 
helped to standardize the size of formed droplets and may 
thus stabilize the formulation.
In the evaluation of the viscosity with a rotation speed 
between 6 and 60 rpm, the viscosity curve was obtained for 
ME, ME50, ME100, EM, EM50 and EM100 (Figure 3). 
The incorporation of PB did not interfere significantly 
with viscosity values for any tested concentrations. The 
tested formulations showed a viscosity with a profile 
characteristic of non-Newtonian fluids, with a reduction 
in apparent viscosity with the increase in rotation speed 
TABLE II - Physicochemical characterization of ME and ME placebo containing PB 5% or 10%
Physicochemical parameter ME ME50 ME100
Resistance centrifugation No phase separation No phase separation No phase separation
pH 5.07±0.09 5.14±0.19 5.11±0.05
Conductivity (µS.cm-1) 33.65±1.66 29.7±1.30* 22.35±2.17**
Refractive index 1,432±0.001 1,380±0.005*** 1,442±0.001**
Particle size(nm) 15.85±1.67 55.05±1.79*** 68.36±3.107***
PDI 0.763±0.20 0.292±0.05* 0.396±0.16
PDI – polydispersity index. *p<0,05; **p<0,01; ***p<0,001 in relation to ME. Student’s t test.
FIGURE 3 - Viscosity curve for microemulsion formulations (A) and conventional emulsion (B). rpm: rotations per minute.
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(Corrêa et al., 2005). The viscosity of the ME proved to 
be approximately 200 times less than the viscosity of 
conventional EMs. This parameter may directly influence 
the drug release profile according to their formulations, 
because formulations with a higher viscosity may have a 
reduced in vitro release drug profile (Chorilli et al., 2007). 
Preliminary stability
In the preliminary evaluation of stability, the 
results were obtained according to Tables III and IV. In 
a stability study, important information can be obtained. 
Emulsified systems, when stored and submitted to several 
external factors, are subjected to the appearance of signs 
of destabilization, such as creaming, sedimentation, 
flocculation, coalescence, phase separation and loss of 
the content of active substances of the formulation (Baby 
et al., 2008).
When stored at room temperature for 30 days, the 
formulations with ME did not show significant changes 
in the evaluated parameters. However, conventional EMs 
showed a significant loss of chemical stability, with a 
reduction in drug content after 30, 60 and 90 days. The 
ME50 and ME100 content was kept for 90 days after 
preparation (Table IV).
In thermal stress and freeze-thaw cycle tests, some 
discreet changes in pH and conductivity values were 
observed for ME, which may be acceptable considering 
the extreme temperature conditions used, ranging from -5 
to 80 °C (Baby et al., 2007). The increased conductivity 
can be related with coalescence, while its decrease can be 
related with aggregation (ANVISA, 2004). Furthermore, 
the ME showed a chemical stability before these tests, 
which was not the case of EM containing PB, with a 
decrease of the drug content up to 80% for thermal stress 
and up to 40% at 90 days of preparation (Table IV). When 
subjected to the freeze-thaw cycle test, the EM maintained 
the drug content, changing only pH and conductivity 
values in EM and EM100 compared to T0. Moreover, 
changes in the conductivity, pH and production of typical 
signs of instability, such as phase separation and creaming, 
were observed for such formulations in the thermal stress 
test (Table III).
Validation of the analytical method to determine 
PB in ME
In order to verify the specificity and selectivity of 
the method, spectrophotometric scans were performed at 
the UV regions 200-400 nm. These analyzed parameters 
TABLE III - Preliminary stability of the formulations tested after 30 days at room temperature, thermal stress and freeze-thaw cycle 
for organoleptic characterization, pH and conductivity
Test ME ME50 ME100 EM EM50 EM100
T0
Organoleptic characterization Normal Normal Normal Normal Normal Normal
pH 5.1±0.1 5.1±0.2 5.1±0.1 5.6±0.3 5.1±0.0 4.9±0.2
Conductivity (μS.cm-1) 33.7±1.7 29.7±1.3 22.4±2.2 35.2±3.7 43.9±1.6 47.5±2.4
T30
Organoleptic characterization Normal Normal Normal Normal Normal Normal
pH 5.1±0.1 5.0±0.0 4.9±0.1 5.3±0.2 4.9±0.1 4.6±0.0
Conductivity (μS.cm-1) 35.5±0.4 32.1±1.6 26.8±2.8 33.9±2.5 42.5±3.8 43.1±1.7
Thermal stress
Organoleptic characterization Normal Normal Normal Phase separ., 
creaming
Phase separ., 
creaming
Phase separ., 
creaming
pH 5.3±0.1* 5.0±0.0 4.9±0.0* 5.1±0.1* 5.1±0.1 5.2±0.1***
Conductivity (μS.cm-1) 30.4±1.0* 27.8±0.7 24.5±1.3 43.6±3.1* 101.1±6.0*** 140.6±6.7***
Freeze-thaw cycle
Organoleptic characterization Normal Normal Normal Normal Normal Normal
pH 5.1±0.1 5.1±0.0 5.1±0.0 5.0±0.0* 4.9±0.1 4.6±0.1*
Conductivity (μS.cm-1) 38.5±2.2* 34.2±0.2** 28.2±0.8* 40.2±2.2 45.6±3.5 54.6±2.9*
T0 – time: 0 days; T30 – time: 30 days. *p<0,05; **p<0,01; ***p<0,001 in relation to T0. Student’s t test. Results were expressed 
as mean ± standard deviation.
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are important in the validation of analytical methods 
to discard interference from impurities, excipients and 
degradation products by determining the amount of a drug 
in the formulation under study (Streck et al., 2011). The 
method was able to perform the determination of the drug 
without a significant interference from ME constituents in 
the region UV λ = 242 nm, where there was no significant 
absorbance of the placebo sample compared to the used 
solvent (data not shown). 
On Table V, the results of the study of linearity, 
precision, accuracy and robustness of the developed 
analytical method are observed. Linearity data were 
subjected to analysis of variance (ANOVA) with 
statistically significant linear regression and without lack 
of adjustments (p <0.05). The values of limit of detection 
(LOD) and limit of quantification (LOQ) are shown on 
Table V, demonstrating the good sensitivity of the method.
Precision is the assessment of the results proximity 
obtained in a series of measurements of a multiple sampling 
of the same sample (ANVISA, 2003). Table 5 shows the 
result of six determinations at a 100% concentration of the 
within-run (repeatability) and between-run (intermediate 
precision) precision tests. There were no statistically 
significant differences between the means of these 
determinations. Moreover, the coefficients of variation 
(CV) were lower than 5% (ICH, 1996). Regarding the 
TABLE IV - Preliminary stability of the formulations tested at 30, 60 and 90 days at room temperature, thermal stress and freeze-
thaw cycle to PB content (%)
Test ME50 ME100 EM50 EM100
T0 96.9±1.3 98.5±2.6 93.5±4.4 103.3±5.5
T30 96.2±1.4 103.9±5.1 83.5±2.3* 93.2±1.5*
T60 100.5±3.5 104.7±3.5 64.9±4.6* 95.5±1.9
T90 97.1±2.0 100.1±1.3 54.2±3.7* 79.6±3.8**
Thermal stress 95.5±5.5 98.2±2.5 32.7±3.4*** 17.5±3.5***
Freeze-thaw cycle 97.5±1.7 101.9±4.0 87.8±4.9 97.5±4.7
T0 – time: 0 days; T30 – time: 30 days; T60 – time: 60 days; T90 – time: 90 days. *p<0,05; **p<0,01; ***p<0,001 in relation to 
T0. Student’s t test. Results were expressed as mean ± standard deviation.
TABLE V - Parameters obtained in validation of the analytical method for determining PB-loaded microemulsion
Parameters Experimental results CV (%) Value p*
Linearity 1 – 24 µg/mL
Straight-line equation y=0.037x – 0.007
Linear correlation coefficient r = 0.9996
LOD 0.409 µg/mL
LOQ 0.619 µg/mL
Precision
Repeatability 12.10±0,48 µg/mL 3.94 0.88261
Intermediate precision 12.05±0,54 µg/mL 4.47
Reproducibility Laborat. A: 11.96±0.16 µg/mL 
Laborat. B: 12.11±0.16 µg/mL
1.32 
1.30
0.13525
Accuracy (%recuperation)
9,6 µg/mL 
12,0 µg/mL 
14,4 µg/mL
100.87±2.12% 
100.29±0.9% 
101.18±0.83%
2.10 
0.9 
0.82
Robustness
Stirring method Manual: 11.85±0.23 µg/mL 
Magnetic: 11.84±0.17 µg/mL
1.97 
1.45
0.9601
Manufacturer solvent Manufact. A: 11.89±0.19 
Manufact. B: 12.07±0.16
1.58 
1.34
0.28184
LOD – limit of detection; LOQ – limit of quantification; CV – coeficient of variation. * Statistical significance at p <0.05, Student’s 
t test.
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assessment of inter-laboratory precision (reproducibility), 
the method also demonstrated a concordance between the 
results obtained in different laboratories when compared 
to measurements with different equipment and the same 
analyst, with p>0.05 (Table V).
The accuracy of the method was evaluated by 
the mean of three determinations at 80% (9.6 µg/
mL), 100% (12 µg/mL) and 120% (14.4 µg/mL) of the 
PB concentration (Table V). Recovery measures the 
efficiency of the extraction procedure of an analytical 
method within a limited variation. Desirable percentages 
are close to 100% (ANVISA, 2003). In all three tested 
concentrations (low, medium and high), the developed 
method demonstrated a percentage of recovery very close 
to 100, with CV lesser than 5%.
For the validation of an analytical method to 
determine a drug in a pharmaceutical formulation, the ability 
of this method to resist small and deliberate variations of 
an analytical parameters should be evaluated. Different 
values of pH, temperature and different manufacturers 
of the solvent used can be evaluated, as well as changes 
in sample preparation (ANVISA, 2003). The developed 
method was considered to be robust regarding the variation 
of the evaluated parameters, comparing manual stirring 
with magnetic stirring and the use of ethanol from different 
manufacturers. No significant differences were observed 
during the preparation of the samples, with p values of 
0.9601 and 0.28184, respectively (Table V). In addition, 
as a parameter for evaluating the robustness of the method, 
the stability of a PB sample in ME was demonstrated at 
100% test concentration (12 µg/mL) in up to 2.5 hours 
(Figure 4). There was a significant loss of approximately 
3.11% of drug content in the presence (p=0.0286) and 
3.08% in the absence of light (p = 0.0260) when comparing 
0 and 3.5 h times. There was no influence of light on sample 
stability loss (p = 0.9189), comparing the 3.5 h time in both 
groups. Therefore, the use of samples prepared within 2 h is 
recommended considering that, although it does not exceed 
10%, the loss is significant. Furthermore, the solution 
EtOH:NaOH used tends to interfere with the method 2 hours 
after preparation (data not shown).
The literature reports several spectrophotometric 
methods to determine drugs in MEs, such as benznidazole 
(Streck et al., 2011), nortriptyline (Moreno et al., 
2000), diazepam (Dastidar, Sa, 2009) and nifedipine 
(Castro, Moreno, Alastres, 2001), as being as effective in 
determining drugs in MEs as HPLC methods (Moreno et 
al., 2000, Silva et al., 2014). From the results obtained, 
it can be shown that the reported analytical method was 
rightfully determined and validated. It proved easy to be 
performed, inexpensive, using few toxic solvents and 
applicable as a quality control method to laboratories 
lacking chromatographic methods. 
Kinetics of the in vitro release of PB in ME
In order to determine the solubility condition for 
the establishment of sink conditions (Klose, Delplace, 
Siepmann, 2011) for the kinetic of the in vitro release of 
PB in ME, a prior study of drug solubility was performed 
using different buffer media and different pH values. The 
borate buffer solution at a pH 9.6 with 10% of EtOH was 
used, for it has a better solubility and does not interfere 
with the wavelength 242 nm (data not shown). A basic 
pH facilitates the solubility of PB (pKa = 7.3) due to its 
conversion into an ionized tautomeric form, in addition 
to increasing its molar absorptivity compared to more 
acidic pHs (Romer, Donaruma, Zuman, 1977; Jelveghari, 
Nokhodchi, 2008). 
Factors such as surfactants/co-surfactants, 
microemulsion type, viscosity, drug solubility, particle 
size, among others, directly influence the behavior of 
drug release (Mortazavi, Pishrochi, Azar, 2013). In 
assessing the kinetics of the in vitro release of PB, ME50 
obtained an amount of PB 4.8 times greater in 24 h 
(17.39 ± 3.13 mg.cm-1) than EM50 (3.84 ± 1.12 mg.cm-1), 
with p=0.0003 for the point 24 h (Figure 5). This result was 
in accordance with the literature, considering that the ME 
is capable of increasing the drug release system (Hashem 
et al., 2011; Kreilgaard, 2002). Thus, the ME provides 
benefits, including increased solubility and absorption of 
drugs, and the possibility of modifying pharmacokinetic 
parameters, decreasing toxicity and increasing its clinical 
efficacy (Formariz et al., 2005; Klein, 2007). 
FIGURE 4 - PB content in the stability study of the same sample 
analyzed within 0-3.5 h in the presence and absence of light 
(n = 3). * p<0.05, compared to time 0h. Parametric t test.
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Besides the influence of droplet size, the presence 
of the co-surfactant used (ethanol) may have contributed 
to the differences observed in the release of PB of the two 
systems. In the obtained ME, ethanol may further reduce 
the surface tension of the surfactant, making the surface 
of droplets more flexible and dynamic. The energy of this 
system facilitates the flow of drugs through the interface 
between the inner and outer layers. This facilitates their 
release and diffusion across membranes (Yi-Hung et al., 
2011). Thus, the study on kinetics of the in vitro release 
showed promising results for MEs, which may provide, 
in the future, a product with transdermal application for 
the treatment of epilepsy.
CONCLUSION
The PB loaded microemulsion developed in this 
work has a great potential for a transdermal delivery 
of the drug. The incorporation of the drug was easily 
accomplished through mild stirring, besides providing 
a great solubilization capacity and little change in its 
physicochemical characteristics with the incorporation of 
the drug. Thus, it demonstrated a physicochemical stability 
greater than EM. The analytical method of determining 
PB in ME can be used as a quality control method, and 
proved easy to be performed and inexpensive. It uses few 
toxic solvents and is applicable to laboratories lacking 
chromatographic methods. Moreover, the ME obtained 
an in vitro release profile significantly greater than EM 
containing PB. Thus, the obtained ME has a potential for 
future transdermal applications, being able to compose a 
drug delivery system for the treatment of epilepsy.
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